Loading company…
Medytox develops and manufactures biopharmaceuticals, including botulinum toxin and hyaluronic acid filler products.
Founded in 2000 and based in South Korea, Medytox develops and manufactures medical compounds, including botulinum toxin type A products, hyaluronic acid fillers, and medical devices. It exports products to approximately 60 countries. In April 2021, Dominus Investment acquired 399,670 shares in Medytox at KRW 162,634 apiece for KRW 65 billion in a PIPE transaction.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in